The Global Health Body Raises Concern Over Acute Shortage of Weight-Loss Medications
Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just access to this class of drugs.
According to forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a lifelong illness that can be addressed with thorough and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad availability to the injections that can help people shift substantial body mass, notes the agency.
Skinny Jab Supply Crisis
Even in the present most optimistic scenario, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of the global need, per the WHO.
The advice encourages governments and firms to widen availability, by approaches such as voluntary licensing.
A patent on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Injections Function
GLP-1 drugs mimick a natural hormone to reduce digestion speed, reduce hunger and boost satiety so people consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Research suggests people may put most of the weight back on a year later of halting the treatment, as their typical food cravings resume.
To be above a healthy weight raises your risk for experiencing medical conditions, like diabetes, cardiovascular issues, stroke, and some cancers.
Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.